vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $151.1M, roughly 1.3× STURM RUGER & CO INC). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 3.6%). STURM RUGER & CO INC produced more free cash flow last quarter ($12.3M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 5.1%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
AXSM vs RGR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $151.1M |
| Net Profit | $-28.6M | — |
| Gross Margin | — | 17.8% |
| Operating Margin | -13.8% | 2.3% |
| Net Margin | -14.6% | — |
| Revenue YoY | 65.0% | 3.6% |
| Net Profit YoY | 61.9% | — |
| EPS (diluted) | $-0.55 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $151.1M | ||
| Q3 25 | $171.0M | $126.8M | ||
| Q2 25 | $150.0M | $132.5M | ||
| Q1 25 | $121.5M | $135.7M | ||
| Q4 24 | $118.8M | $145.8M | ||
| Q3 24 | $104.8M | $122.3M | ||
| Q2 24 | $87.2M | $130.8M | ||
| Q1 24 | $75.0M | $136.8M |
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $1.6M | ||
| Q2 25 | $-48.0M | $-17.2M | ||
| Q1 25 | $-59.4M | $7.8M | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $4.7M | ||
| Q2 24 | $-79.3M | $8.3M | ||
| Q1 24 | $-68.4M | $7.1M |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 21.5% |
| Q4 25 | -13.8% | 2.3% | ||
| Q3 25 | -27.0% | -2.7% | ||
| Q2 25 | -24.5% | -15.6% | ||
| Q1 25 | -46.9% | 6.2% | ||
| Q4 24 | -61.1% | 7.8% | ||
| Q3 24 | -59.8% | 3.1% | ||
| Q2 24 | -89.5% | 6.9% | ||
| Q1 24 | -89.7% | 5.5% |
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | 1.2% | ||
| Q2 25 | -32.0% | -13.0% | ||
| Q1 25 | -48.9% | 5.7% | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | 3.9% | ||
| Q2 24 | -91.0% | 6.3% | ||
| Q1 24 | -91.1% | 5.2% |
| Q4 25 | $-0.55 | $0.22 | ||
| Q3 25 | $-0.94 | $0.10 | ||
| Q2 25 | $-0.97 | $-1.05 | ||
| Q1 25 | $-1.22 | $0.46 | ||
| Q4 24 | $-1.54 | $0.62 | ||
| Q3 24 | $-1.34 | $0.28 | ||
| Q2 24 | $-1.67 | $0.47 | ||
| Q1 24 | $-1.44 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $92.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $283.8M |
| Total Assets | $689.8M | $342.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $92.5M | ||
| Q3 25 | $325.3M | $80.8M | ||
| Q2 25 | $303.0M | $101.4M | ||
| Q1 25 | $300.9M | $108.3M | ||
| Q4 24 | $315.4M | $105.5M | ||
| Q3 24 | $327.3M | $96.0M | ||
| Q2 24 | $315.7M | $105.6M | ||
| Q1 24 | $331.4M | $115.3M |
| Q4 25 | $88.3M | $283.8M | ||
| Q3 25 | $73.7M | $279.6M | ||
| Q2 25 | $73.1M | $289.3M | ||
| Q1 25 | $53.2M | $321.5M | ||
| Q4 24 | $57.0M | $319.6M | ||
| Q3 24 | $92.9M | $314.9M | ||
| Q2 24 | $102.9M | $321.5M | ||
| Q1 24 | $144.0M | $332.0M |
| Q4 25 | $689.8M | $342.0M | ||
| Q3 25 | $669.3M | $342.3M | ||
| Q2 25 | $639.8M | $349.5M | ||
| Q1 25 | $596.7M | $379.0M | ||
| Q4 24 | $568.5M | $384.0M | ||
| Q3 24 | $561.5M | $373.5M | ||
| Q2 24 | $548.2M | $376.7M | ||
| Q1 24 | $545.7M | $385.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $15.5M |
| Free Cash FlowOCF − Capex | $-18.7M | $12.3M |
| FCF MarginFCF / Revenue | -9.6% | 8.2% |
| Capex IntensityCapex / Revenue | 0.0% | 2.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $15.5M | ||
| Q3 25 | $1.0M | $12.9M | ||
| Q2 25 | $-32.4M | $14.7M | ||
| Q1 25 | $-43.4M | $11.1M | ||
| Q4 24 | $-26.2M | $20.0M | ||
| Q3 24 | $-18.6M | $9.4M | ||
| Q2 24 | $-30.1M | $18.7M | ||
| Q1 24 | $-53.5M | $7.3M |
| Q4 25 | $-18.7M | $12.3M | ||
| Q3 25 | $988.0K | $7.0M | ||
| Q2 25 | $-32.4M | $9.1M | ||
| Q1 25 | $-43.7M | $10.0M | ||
| Q4 24 | $-26.2M | $16.4M | ||
| Q3 24 | $-18.7M | $2.6M | ||
| Q2 24 | $-30.2M | $10.1M | ||
| Q1 24 | $-53.6M | $5.6M |
| Q4 25 | -9.6% | 8.2% | ||
| Q3 25 | 0.6% | 5.5% | ||
| Q2 25 | -21.6% | 6.9% | ||
| Q1 25 | -36.0% | 7.4% | ||
| Q4 24 | -22.1% | 11.2% | ||
| Q3 24 | -17.9% | 2.1% | ||
| Q2 24 | -34.6% | 7.7% | ||
| Q1 24 | -71.4% | 4.1% |
| Q4 25 | 0.0% | 2.1% | ||
| Q3 25 | 0.0% | 4.6% | ||
| Q2 25 | 0.0% | 4.2% | ||
| Q1 25 | 0.3% | 0.8% | ||
| Q4 24 | 0.0% | 2.5% | ||
| Q3 24 | 0.1% | 5.5% | ||
| Q2 24 | 0.1% | 6.6% | ||
| Q1 24 | 0.1% | 1.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
